Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Bladder Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
27 drugs · 88 active trials
2 drugs · 4 active trials
10 drugs · 164 active trials
Data updated 7 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Sunitinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 11 | 0 | — | — | 2006-05 |
| Trastuzumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 7 | 0 | — | — | 2000-03 |
| Pegfilgrastim | Phase 2 | Phase 2 | 1 | 0 | 0 | 5 | 0 | — | — | 2007-04 |
| Irinotecan | Phase 2 | Phase 2 | 1 | 0 | 0 | 4 | 0 | — | — | 1999-08 |
| Nab-paclitaxel | Phase 2 | Phase 2 | 1 | 1 | 0 | 4 | 0 | — | — | 2016-06 |
| Oxaliplatin | Phase 2 | Phase 2 | 1 | 0 | 0 | 4 | 0 | — | — | 2000-02 |
| Aldesleukin | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | Jul 3, 2014 |
| Olaparib | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | Nov 16, 2018 |
| Romidepsin | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | 2004-06 |
| Trastuzumab Emtansine | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | Aug 17, 2015 |
| Afatinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Palbociclib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Pertuzumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Apr 14, 2014 |
| Vismodegib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Apr 14, 2014 |
| Adavosertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Adebrelimab | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Nov 16, 2023 |
| Binimetinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Cabazitaxel | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Dec 1, 2014 |
| Camizestrant | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Nov 12, 2020 |
| Capivasertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Copanlisib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Crizotinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Dabrafenib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Dasatinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Fexagratinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Futibatinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Dec 30, 2024 |
| Immunotherapy | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Apr 29, 2021 |
| Ipatasertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Ipilimumab/Nivolumab Regimen | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Mar 14, 2022 |
| Larotrectinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Osimertinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Tarlatamab | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Sep 8, 2025 |
| Taselisib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Tazemetostat | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Nov 18, 2019 |
| Trametinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Trastuzumab Deruxtecan | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Nov 12, 2020 |
| Ifosfamide | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | 1995-05 |
| Erlotinib Hydrochloride | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2001-12 |
| Pazopanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2008-08 |
| Sorafenib | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2006-10 |
| Everolimus | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | Dec 5, 2008 |
| Sorafenib Tosylate | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2005-04 |
| Tisotumab Vedotin | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | Nov 30, 2013 |
| Bortezomib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2003-09 |
| Cetuximab | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2008-03 |
| Enzalutamide | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Feb 11, 2015 |
| Erlotinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2006-05 |
| Temsirolimus | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2008-02 |
| Tipifarnib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2000-03 |
| Vandetanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2006-09 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.